http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김주현,김대연,김준환,NOH JOSEPH JOONHO,황우연,백민현,최민철,주원덕,이용재,서동훈,김용범 대한부인종양학회 2024 Journal of Gynecologic Oncology Vol.35 No.2
The Korean Society of Gynecologic Oncology (KSGO) had been making an effort tostandardize and enhance the quality of domestic uterine corpus cancer treatment bydeveloping updated clinical practice guidelines in 2021. The KSGO revised the guidelinesbased on a literature search using 4 key elements: Population, Inter vention, Comparison,and Outcome framework. These elements include the evaluation of the efficacy and safety ofimmune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patientswho have failed platinum-based chemotherapy, as well as the effect of combined treatmentwith trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally,the guideline assessed the efficacy and safety of omitting lymph node dissection in low-riskendometrial cancer patients, investigated the effect of sentinel lymph node mapping inearly-stage endometrial cancer surger y, addressed the outcome of chemoradiation therapy asa postoperative treatment in patients with advanced (stage III–IVA) endometrial cancer, andexplored the impact of initial treatment with immune checkpoint inhibitors on sur vival inpatients with advanced or recurrent endometrial cancer patients.
심승혁,이정윤,이유영,박정열,이용재,김세익,한관희,양은정,NOH JOSEPH JOONHO,임가원,손주혁,김남경,김태현,공태욱,최윤진,조안젤라,임현지,장은비,조현웅,서동훈 대한부인종양학회 2024 Journal of Gynecologic Oncology Vol.35 No.2
In the 2023 series, we summarized the major clinical research advances in gynecologiconcology based on communications at the conference of Asian Society of GynecologicOncology Review Course. The review consisted of 1) Endometrial cancer: immunecheckpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export,CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2)Cer vical cancer: surger y in low-risk early-stage cer vical cancer, therapy for locally advancedstage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy,triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents andPARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnesseda landmark year, marked by several practice-changing outcomes with immune checkpointinhibitors and the reliable efficacy of PARP inhibitors and ADCs.